Morten Hanefeld Dziegiel
2200 København N.
1984 cand.med. University of Copenhagen
1992 PhD, University of Copenhagen
1999 Medical Specialist in Clinical Immunology
2005 Management course (RL6) at Copenhagen University Hospital, Rigshospitalet
POSITIONS for TRAINING, RESEARCH, CLINICAL WORK and TEACHING
1987 Statens Serum Institut
1991 Introductory position, clinical immunology, Rigshospitalet
1993 - 1996 MRC fellowship
2000-2002 Medical Staff member, Blood bank, Rigshospitalet
2002- Chief physician, Head of Unit of Immunohaematology and blood genetics, Blood bank, Rigshospitalet
2005- Associate professor, University of Copenhagen, Institut for Klinisk Medicin
2011- Postgraduate associate professor, University of Copenhagen, Institut for Klinisk Medicin
TEACHING, SUPERVISION and ASSESSMENT
1996 - 2005 Clinical immunology and transfusion medicine for midwife students
2005 - Clinical immunology and transfusionsmedicince at the Medical Faculty KU for
2008 - Course leader for National Board of Health A-course in 'Erythrocyte – and
Supervisor for 7 master students (cand.scient.stud), 5 medical students and 4
PhD-students. Assessor of 5 PhD theses, 1 Norwegian and 1 Swedish Doctoral theses
INTERNATIONAL RESEARCH COOPERATION and MANAGEMENT
- Initiated and coordinated EU financed BioMed BMH4 project
- Associated proposer in EU program TS3
- Associated member of EU collaboration on Special Non-invasive Advances in Fetal and Neonatal Evaluation (SAFE)
ADVISORY POSTS for HEALTH AUTHORITIES
2006 - Adviser for The Danish National Board of Health (Sundhedsstyrelsen)
2011 Evaluator for The Swedish SBU (Statens beredning för medicinsk utvärdering)
2014 Adviser for the Norwegian Kunnskapssenteret
- Articles: 94 published
- Patents/applications: 18/2. Text book chapters 4, E-learning program 1.
- H-index = 33 (Google scholar), a total of 2964 citations, i10-index = 69.
- Publications in Nature Medicine, BLOOD
SCIENTIFIC, CLINICAL and SOCIETAL IMPACT
The recombinant anti-D antibodies from my laboratory are used in clinical routine. The antenatal RHD screening developed by my laboratory was implemented nationally in Denmark and enabled in 2010 the first targetted antenatal Rh prophylaxis in the world. We are in the process of evaluating the national effect of the supplementary antenatal prophylaxis implemented in 2010.
SCIENTIFIC SOCIETIES and CONFERENCES
Chairman for Dansk Selskab for Reproduktion og Fosterudvikling 2009-2013, member of Dansk Selskab for Klinisk Immunologi, Biokemisk Forening, International Society of Blood Transfusion (ISBT). Member of the organizing commitee for CfDNA-2013 June 2013, Copenhagen.